Construction and characterization of a Pseudomonas aeruginosa mucoid exopolysaccharide-alginate conjugate vaccine

Infection and Immunity

Volumn 71, Issue 7, 2003, Pages 3875-3884

  Theilacker, Christian ^a   Coleman, Fadie T ^a   Mueschenborn, Simone ^a   Llosa, Nicolas ^a   Grout, Martha ^a   Pier, Gerald B ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALGINIC ACID; BACTERIAL POLYSACCHARIDE; CARBOXYLIC ACID DERIVATIVE; CROSS REACTING ANTIBODY; EPITOPE; EXOPOLYSACCHARIDE KEYHOLE LIMPET HEMOCYANIN CONJUGATE VACCINE; IMMUNOGLOBULIN G; PSEUDOMONAS VACCINE; SCOGIN; SUCCINIMIDYL 4 (N MALEIMIDOMETHYL)CYCLOHEXANE 1 CARBOXYLATE; UNCLASSIFIED DRUG; URONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CROSS REACTION; DRUG CONJUGATION; DRUG MIXTURE; DRUG SYNTHESIS; GRAM NEGATIVE INFECTION; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; OPSONIZATION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RABBIT; SEAWEED; TIME SERIES ANALYSIS;

ALGINATES; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; BLOOD BACTERICIDAL ACTIVITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; HEMOCYANIN; MICE; MICE, INBRED C3H; POLYSACCHARIDES, BACTERIAL; PSEUDOMONAS AERUGINOSA; RABBITS; VACCINES, CONJUGATE;

EID: 0038538285     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.71.7.3875-3884.2003     Document Type: Article

References (42)

1. Berry, D. S., F. Lynn, C. H. Lee, C. E. Frasch, and M. C. Bash. 2002. Effect of O acetylation of Neisseria meningitidis serogroup A capsular polysaccharide on development of functional immune responses. Infect. Immun. 70:3707-3713.
2. Bradford, M. M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:248-254.
3. Coleman, F. T., S. Mueschenborn, G. Meluleni, C. Ray, V. J. Carey, S. O. Vargas, C. L. Cannon, F. M. Ausubel, and G. B. Pier. 2003. Hypersusceptibility of cystic fibrosis mice to chronic Pseudomonas aeruginosa oropharyngeal colonization and lung infection. Proc. Natl. Acad. Sci. USA 100:1949-1954.
4. Cryz, S. J., Jr., E. Furer, and J. U. Que. 1991. Synthesis and characterization of a Pseudomonas aeruginosa alginate-toxin A conjugate vaccine. Infect. Immun. 59:45-50.
5. Demko, C. A., P. J. Byard, and P. B. Davis. 1995. Gender differences in cystic fibrosis: Pseudomonas aeruginosa infection. J. Clin. Epidemiol. 48:1041-1049.
6. Ellman, G. L. 1959. Tissue sulfhydryl groups. Arch. Biochem. Biophys. 82:70-77.
7. Fattom, A., J. Shiloach, D. Bryla, D. Fitzgerald, I. Pastan, W. W. Karakawa, J. B. Robbins, and R. Schneerson. 1992. Comparative immunogenicity of conjugates composed of the Staphylococcus aureus type 8 capsular polysaccharide bound to carrier proteins by adipic acid dihydrazide or N-succinimidyl-3-(2-pyridyldithio)propionate. Infect. Immun. 60:584-589.
8. Fattom, A. I., J. Sarwar, L. Basham, S. Ennifar, and R. Naso. 1998. Antigenic determinants of Staphylococcus aureus type 5 and type 8 capsular polysaccharide vaccines. Infect. Immun. 66:4588-4592.
9. Filisetti-Cozzi, T. M., and N. C. Carpita. 1991. Measurement of uronic acids without interference from neutral sugars. Anal. Biochem. 197:157-162.
10. Garner, C. V., D. DesJardins, and G. B. Pier. 1990. Immunogenic properties of Pseudomonas aeruginosa mucoid exopolysaccharide. Infect. Immun. 58:1835-1842.
11. Gilewski, T., S. Adluri, G. Ragupathi, S. Zhang, T. J. Yao, K. Panageas, M. Moynahan, A. Houghton, L. Norton, and P. O. Livingston. 2000. Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Clin. Cancer Res. 6:1693-1701.
12. Grasdalen, H. 1983. High-field, 1H-NMR spectroscopy of alginate: sequential structure and linkage conformations. Carbohydr. Res. 118:255-260.
13. Helling, F., A. Shang, M. Calves, S. Zhang, S. Ren, R. K. Yu, H. F. Oettgen, and P. O. Livingston. 1994. GD3 vaccines for melanoma: superior immunogenicity of keyhole limpet hemocyanin conjugate vaccines. Cancer Res. 54:197-203.
14. Hermanson-GT. 1996. Bioconjugate techniques. Academic Press, Inc., San Diego, Calif.
15. Johansen, H. K., F. Espersen, S. J. Cryz, Jr., H. P. Hougen, A. Fomsgaard, J. Rygaard, and N. Hoiby. 1994. Immunization with Pseudomonas aeruginosa vaccines and adjuvant can modulate the type of inflammatory response subsequent to infection. Infect. Immun. 62:3146-3155.
16. Johansen, H. K., H. P. Hougen, S. J. Cryz, Jr., J. Rygaard, and N. Hoiby. 1995. Vaccination promotes TH1-like inflammation and survival in chronic Pseudomonas aeruginosa pneumonia in rats. Am. J. Respir. Crit. Care Med. 152:1337-1346.
17. Kossaczka, Z., F. Y. Lin, V. A. Ho, N. T. Thuy, P. Van Bay, T. C. Thanh, H. B. Khiem, D. D. Trach, A. Karpas, S. Hunt, D. A. Bryla, R. Schneerson, J. B. Robbins, and S. C. Szu. 1999. Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam. Infect. Immun. 67:5806-5810.
18. Laferriere, C. A., R. K. Sood, J. M. de Muys, F. Michon, and H. J. Jennings. 1998. Streptococcus pneumoniae type 14 polysaccharide-conjugate vaccines: length stabilization of opsonophagocytic conformational polysaccharide epitopes. Infect. Immun. 66:2441-2446.
19. Lin, F. Y., V. A. Ho, H. B. Khiem, D. D. Trach, P. V. Bay, T. C. Thanh, Z. Kossaczka, D. A. Bryla, J. Shiloach, J. B. Robbins, R. Schneerson, S. C. Szu, M. N. Lanh, S. Hunt, L. Trinh, and J. B. Kaufman. 2001. The efficacy of a Salmonella typhi Vi conjugate vaccine in two- to-five-year-old children. N. Engl. J. Med. 344:1263-1269.
20. Lindberg, A. A. 1999. Glycoprotein conjugate vaccines. Vaccine 17(Suppl. 2):S28-S36.
21. Lyczak, J. B., C. L. Cannon, and G. B. Pier. 2002. Lung infections associated with cystic fibrosis. Clin. Microbiol. Rev. 15:194-222.
22. Meluleni, G. J., M. Grout, D. J. Evans, and G. B. Pier. 1995. Mucoid Pseudomonas aeruginosa growing in a biofilm in vitro are killed by opsonic antibodies to the mucoid exopolysaccharide capsule but not by antibodies produced during chronic lung infection in cystic fibrosis patients. J. Immunol. 155:2029-2038.
23. Michon, F., C. H. Huang, E. K. Farley, L. Hronowski, J. Di, and P. C. Fusco. 2000. Structure activity studies on group C meningococcal polysaccharide-protein conjugate vaccines: effect of O-acetylation on the nature of the protective epitope. Dev. Biol. 103:151-160.
24. Musselli, C., P. O. Livingston, and G. Ragupathi. 2001. Keyhole limpet hemocyanin conjugate vaccines against cancer: the Memorial Sloan Kettering experience. J. Cancer Res. Clin. Oncol. 127(Suppl. 2):R20-R26.
25. Ohman, D. E., and A. M. Chakrabarty. 1981. Genetic mapping of chromosomal determinants for the production of the exopolysaccharide alginate in a Pseudomonas aeruginosa cystic fibrosis isolate. Infect. Immun. 33:142-148.
26. Onsoyen, E. 1996. Commercial applications of alginates. Carbohydr. Eur. 14:26-31.
27. Pier, G. B., F. Coleman, M. Grout, M. Franklin, and D. E. Ohman. 2001. Role of alginate O-acetylation in the resistance of mucoid Pseudomonas aeruginosa to opsonic phagocytosis. Infect. Immun. 69:1895-1901.
28. Pier, G. B., D. DesJardin, M. Grout, C. Garner, S. E. Bennett, G. Pekoe, S. A. Fuller, M. O. Thornton, W. S. Harkonen, and H. C. Miller. 1994. Human immune response to Pseudomonas aeruginosa mucoid exopolysaccharide (alginate) vaccine. Infect. Immun. 62:3972-3979.
29. Pier, G. B., D. Desjardins, T. Aguilar, M. Barnard, and D. P. Speert. 1986. Polysaccharide surface antigens expressed by nonmucoid isolates of Pseudomonas aeruginosa from cystic fibrosis patients. J. Clin. Microbiol. 24:189-196.
30. Pier, G. B., M. Grout, and D. Desjardins. 1991. Complement deposition by antibodies to Pseudomonas aeruginosa mucoid exopolysaccharide (MEP) and by non-MEP specific opsonins. J. Immunol. 147:1869-1876.
31. Pier, G. B., W. J. Matthews, Jr., and D. D. Eardley. 1983. Immunochemical characterization of the mucoid exopolysaccharide of Pseudomonas aeruginosa. J. Infect. Dis. 147:494-503.
32. Pier, G. B., J. M. Saunders, P. Ames, M. S. Edwards, H. Auerbach, J. Goldfarb, D. P. Speert, and S. Hurwitch. 1987. Opsonophagocytic killing antibody to Pseudomonas aeruginosa mucoid exopolysaccharide in older non-colonized patients with cystic fibrosis. N. Engl. J. Med. 317:793-798.
33. Pier, G. B., G. J. Small, and H. B. Warren. 1990. Protection against mucoid Pseudomonas aeruginosa in rodent models of endobronchial infections. Science 249:537-540.
34. Ragupathi, G., R. R. Koganty, D. Qiu, K. O. Lloyd, and P. O. Livingston. 1998. A novel and efficient method for synthetic carbohydrate conjugate vaccine preparation: synthesis of sialyl Tn-KLH conjugate using a 4-(4-N-maleimidomethyl)cyclohexane-1-carboxyl hydrazide (MMCCH) linker arm. Glycoconj. J. 15:217-221.
35. Sherbrock-Cox, V., N. J. Russell, and P. Gacesa. 1984. The purification and chemical characterization of the alginate present in extracellular material produced by mucoid strains of Pseudomonas aeruginosa. Carbohydr. Res. 135:147-154.
36. Skjak-Braek, G., H. Grasdalen, and B. Larsen. 1986. Monomer sequence and acetylation pattern in some bacterial alginates. Carbohydr. Res. 154:239-250.
37. Slovin, S. F., G. Ragupathi, S. Adluri, G. Ungers, K. Terry, S. Kim, M. Spassova, W. G. Bornmann, M. Fazzari, L. Dantis, K. Olkiewicz, K. O. Lloyd, P. O. Livingston, S. J. Danishefsky, and H. I. Scher. 1999. Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man. Proc. Natl. Acad. Sci. USA 96:5710-5715.
38. Szu, S. C., S. Bystricky, M. Hinojosa-Ahumada, W. Egan, and J. B. Robbins. 1994. Synthesis and some immunologic properties of an O-acetyl pectin [poly(1→4)-alpha-D-GalpA]-protein conjugate as a vaccine for typhoid fever. Infect. Immun. 62:5545-5549.
39. Szu, S. C., A. L. Stone, J. D. Robbins, R. Schneerson, and J. B. Robbins. 1987. Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals. J. Exp. Med. 166:1510-1524.
40. van de Wiel, P. A., M. H. Witvliet, D. Evenberg, H. J. Derks, and E. C. Beuvery. 1987. O-polysaccharide-protein conjugates induce high levels of specific antibodies to Pseudomonas aeruginosa immunotype 3 lipopolysaccharide. Vaccine 5:33-38.
41. Worlitzsch, D., R. Tarran, M. Ulrich, U. Schwab, A. Cekici, K. C. Meyer, P. Birrer, G. Bellon, J. Berger, T. Weiss, K. Botzenhart, J. R. Yankaskas, S. Randell, R. C. Boucher, and G. Doring. 2002. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J. Clin. Investig. 109:317-325.
42. Young, S. S., M. Kharrazi, M. Pearl, and G. Cunningham. 2001. Cystic fibrosis screening in newborns: results from existing programs. Curr. Opin. Pulmon. Med. 7:427-433.